Image source: Shutterstock

Highlights

  • Entero Therapeutics finalizes a rescission agreement with all previous shareholders of ImmunogenX, subject to shareholder approval by June 30, 2025.

  • Anna Skowron appointed as Chief Financial Officer, effective March 3, 2025.

Entero Therapeutics, Inc. (NASDAQ:ENTO), a clinical-stage biopharmaceutical company specializing in targeted therapies for gastrointestinal diseases, has successfully reached an agreement to rescind its previously completed business combination with ImmunogenX, LLC. The rescission agreement, signed with all former ImmunogenX shareholders, is subject to certain conditions, including shareholder approval, which must be obtained by June 30, 2025.

The initial business combination was announced on December 18, 2023, and finalized on March 14, 2024. However, following negotiations, Entero and ImmunogenX shareholders agreed to unwind the transaction. 

In addition to the rescission announcement, Entero has named Anna Skowron as its new Chief Financial Officer, effective March 3, 2025. Ms. Skowron brings extensive expertise in financial reporting, compliance, and corporate governance. She founded Skowron Accounting Professional Corporation in 2015 and has accumulated over 14 years of experience in accounting and financial management.

Prior to joining Entero, Ms. Skowron served as Global Financial Controller for a North American technology provider and oversaw consolidated reporting for a global steel corporation. Her experience includes significant involvement in business acquisitions and capital-raising efforts across multiple industries. She holds a Bachelor of Commerce and Finance from the University of Toronto and became a member of the Institute of Chartered Accountants of Ontario in 2014.